Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

Inclusion Criteria: * Histologically or cytologically confirmed evidence of metastatic/ unresectable uveal melanoma * Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension and is ≥10 mm by spiral CT scan * 18 years or older * Eastern Cooperative Oncology Group(ECOG)performance status 0, or 1 * No known HIV or Hepatitis B or C * Patients with brain metastasis are eligible for entry into the study * Patients must have normal organ/marrow function as defined below: * Absolute neutrophil count ≥ 1.5 x 109/L * Platelets ≥ 100,000 x 109/L * Hemoglobin ≥ 9.0 gm/100 ml * Total bilirubin ≤ 1.5. In patients with Gilbert's disease the indirect bilirubin must be less than or equal to 4.0. * AST and ALT ≤ 2.5x upper limit of normal * Alkaline phosphatase ≤ 2.5x upper limit of normal, unless bone metastases is present in the absence of liver metastasis * Creatinine ≤ 1.8 mg/ml or calculated creatinine clearance \> 50 mg ml. * Calcium \<12 mg/dl when corrected for levels of serum albumen * Patients my have had up to one prior systemic therapy Exclusion Criteria: * Chemotherapy or radiotherapy within 4 weeks prior to entering the study or failure to recover from adverse events due to agents administered more than 4 weeks earlier. * May not be receiving any other simultaneous investigational agents * No prior malignancy except for adequately treated basal cell cancer, in situ cervical cancer or other cancer for which t…